Tyra BiosciencesTYRA
Recorded

Tyra Biosciences Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Maury RaycroftAnalyst

I am one of the biotech analysts at Jefferies. I would like to welcome the CEO of Tyra Biosciences. We have Todd Harris, and Todd is going to give some slides at the beginning, provide an intro to the company, and then we will go into fireside chat. I would like to turn it over to Todd. Thanks for joining us. All right.

Todd HarrisCEO

Thanks, Maury, and good morning, everyone. We will be making some forward-looking statements today, so please be advised. I want to talk about focus for Tyra going into 2027. We have been talking about over the last year our dabogratinib 3x3 strategy. Tyra is a precision medicine company focused in the FGFR family with a lead compound that is a first FGFR3 selective oral small molecule inhibitor to make it in the clinic. This is actually a molecule that we made ourselves. It is homegrown through our structured-based drug design approach that we call our SNÅP chemistry platform. We read out some very compelling data this fall in our intermediate-risk NMIBC study. On the back of that, we had a $400 million raise.

Todd HarrisCEO

We have a balance sheet now of $700 million, where we are going to be prosecuting two of the big indications, two both blockbuster indications in our dabogratinib 3x3 strategy for urothelial carcinoma. This includes the intermediate-risk NMIBC opportunity, a multi-blockbuster opportunity, as well as the upper tract urothelial carcinoma indication, a very high unmet need indication where patients typically lose their kidney. You can expect this year that we are going to be launching our phase III in intermediate-risk NMIBC in 2027, as well as updating our SURF302 data, our phase II data, with longer term safety and efficacy. We will also be reading out our dose selection data for the low-grade upper tract urothelial carcinoma study. We also have a program, another blockbuster indication with this molecule, dabogratinib, in achondroplasia. We will be reading out dose selection data as well in 2027.

Todd HarrisCEO

I want to start framing a really important part of our story that we believe is underappreciated by investors, urologists, and the market broadly around the size of the opportunity for oral maintenance in urothelial carcinoma. We believe there is an $18 billion-$36 billion total addressable market for an oral therapy. Why do we believe that? It is based off of really three simple things. First, there are roughly 38,000 new patients a year presenting with intermediate-risk NMIBC or low-grade UTUC. Oral maintenance therapy is a therapy that you are going to need to be on that we are studying for at least two years, and potentially patients would want to be on longer to prevent recurrence, and we will talk about that as we get into the market. If you look at pricing, reference pricing in this space, from ADSTILADRIN to Erleada, we are talking about $240,000-$480,000 a year pricing.

Todd HarrisCEO

Multiply those three together and you get this number. It's very, very large. We stand alone as leaders making this market. There are two other companies that are also pursuing this space, and they're the two largest pharmaceutical companies in the world, Eli Lilly and J&J. This is a very important space, and this is very important innovation for patients. Let's talk about the market. I want to begin with the intermediate-risk NMIBC market. Today, the vast majority of patients are actually foregoing a guideline-mandated treatment of intravesical therapy, and instead waiting to recur. Why are they doing that? Because in the intermediate-risk NMIBC setting, the unmet need is that patients will recur, and they will recur quite frequently. Progression is actually a low risk, but the cost and the disruption from procedures is actually the biggest unmet need for these patients.

Todd HarrisCEO

They would rather forego an effective therapy that requires six to 30 visits to the urologist with intravesical therapies and simply wait to recur and undergo a surgery under general anesthesia that is TURBT. Patients are voting with their feet today. They do not want the procedures, and they're not taking the procedures for maintenance. When we look at what's driving all of this recurrence, FGFR3 is clearly the driver. This was data shared this year from Dr. Meeks at AUA. What it highlights is that when you do the FGFR3 genotyping, it is the patients that are FGFR3 positive that are recurring most frequently, with a median recurrence-free survival of 16 months versus 40 months if you're FGFR3 negative. If we can suppress FGFR3 continually, we have the opportunity to bend the disease-free survival curve for these patients to potentially prolong the time by which they may recur.

Todd HarrisCEO

The evidence has already been generated. Initially, J&J did some great work with both TAR-210 oral erdafitinib, that as long as you stay on therapy, the durability of FGFR3 suppression in preventing recurrence is 100%. As soon as patients come off of therapy, we see in the TAR-210 phase II, three out of four recurred within three months. What this tells us is that constant FGFR3 suppression is needed to maintain disease-free survival. When we look at the space and we look at the various approaches to try and maintain disease-free survival, all of the phase III approaches today preceding us have been intravesical therapies. So, these are therapies that require you to go to the office, have the installation, have a viral vector, or have chemotherapy, or have a pretzel installed.

Todd HarrisCEO

We already know from the market that patients are choosing not to have these repeat catheterizations to try and maintain disease. Only one of these, TAR-210, is actually targeting FGFR3, which is the main driver of recurrence. Our approach with oral dabogratinib is the only once-a-day oral therapy that could potentially break in and introduce this very attractive oral maintenance market for patients. Now, we believe oral dabogratinib is actually complementary to all of the intravesical and surgical approaches that are starting to emerge. Why do we believe that? Well, when a patient presents with a new tumor or a recurrent tumor, they have options today. Today, they could undergo general anesthesia and a TURBT procedure. They could also get six installations of Zusduri to ablate that tumor. But what happens next? Well, the patients are now on the path, especially if they're FGFR3 positive, for potential recurrence.

Todd HarrisCEO

There are a variety of different approaches to induce a better response with TAR-210, ADSTILADRIN, CG Oncology, and others reading out phase III studies in this adjuvant setting. What we've already learned from the market is that over time, patients fatigue from intravesical therapies. We believe dabogratinib is truly complementary to all of these approaches, because whether you start on dabogratinib for ablation, start on it for induction, or start on it after you have an initial induction with some of these intravesical approaches, long-term maintenance can be achieved by taking a once-daily pill to control your disease. This is why all of the patients that are presenting ultimately are eligible patients to go on dabogratinib. Why do we believe we're going to be successful?

Todd HarrisCEO

With the data that we just read out this fall from our SURF302 study, this was a marker lesion study in the ablative setting. We actually showcased that for patients that had a small single marker lesion left behind, the response rate in three months from taking oral dabogratinib was 100% with a 75% CR rate. The tolerability was exceptional, supporting chronic oral dosing for years. It's on the basis of this that we're now moving into our maintenance, our adjuvant phase III study, aligning with regulators on that approach, which we are intending to be a placebo-controlled study, and taking the 60 milligram dose that generated these data into that study. We believe this is a high probability of success phase III. Why do we believe that?

Todd HarrisCEO

Well, first off, because we have that median recurrence-free survival data shared this year from Dr. Meeks in the FGFR3-positive population, we can project that on placebo, so patients that are opting not for intravesical therapies, that are just waiting to recur, which is where the vast majority of the patients are today, at two years, the disease-free survival is estimated to be at 36%. That means 64% of patients are at risk. We can take the data we just generated on CR rates, PR rates. In the most conservative scenario, we're going to look for a hazard ratio of 0.6. The reality is, if we look at the single marker lesion data we just read out, 100% OR, 75% CR, we're projecting a very attractive disease-free survival curve, one that would generate a very compelling hazard ratio as patients stay on this therapy out for two years.

Todd HarrisCEO

Let's talk about the market. This is a market creation story. It's driven by two key segments today. The vast majority of patients are not undergoing any maintenance therapy, but there is a small proportion of patients that are at least starting on induction maintenance chemotherapy. That's 30% of the market. In that market, we have an opportunity to win on efficacy and, of course, convenience for those patients that are today choosing to undergo intravesical therapies to try and control their disease. For those that start with instrumentation, we have an opportunity to switch them onto oral dabogratinib for long-term maintenance. We just completed a 150-patient survey testing this profile of oral dabogratinib against the other options for these patients.

Todd HarrisCEO

These are physicians that are community urologists, and this is important because to get at that community urologist, this is where the vast majority of patients are being treated, not in the academic medical center. The average urologist that we tested here, that we surveyed, treats about 43 patients a year, spends 90% of their time in patient care, and remarkably, 87% of our 150 urologists that we surveyed already has an in-office dispensed pharmacy. We will talk a little bit more about why that is important, but they are generating practice revenue by having their own pharmacy for some of the prostate cancer drugs.

Todd HarrisCEO

Now, when testing this profile, the vast majority of urologists said, "We would love to start with oral dabogratinib." Even for those that start on a device, TAR-210 or some intravesical approach, because of the attractiveness of an oral, fewer repeat catheterizations, a less invasive experience for their patients, we anticipate that oral dabogratinib could be used both initially or even after or complementary to initiating patients on, say, TAR-210 for ablation and even initial induction. Let us talk about the in-office dispense pharmacy. This is very important. It is an evolution over the last 15 years due to the prostate cancer drugs like XTANDI. Physicians have learned that by setting up their own in-office dispense pharmacy, they can share in the spread of the revenue generated from an oral drug, and it has become a major driver of their practice. This is old data, 2021.

Todd HarrisCEO

If you fast-forward to today, 2026, these community urologists, most of them are making 50% of their practice revenue from the spread they get on prescribing XTANDI, ORGOVYX, Erleada, the prostate cancer drugs. It is a major driver of the economics for the practice or for the economics of the private equity groups that own many of these practices. Over the next couple years, XTANDI and some of the other oral prostate cancer drugs are going to go off patent. This will generate a giant hole in the practice revenue for many urologists. It is for this reason that when we go out and talk about oral dabogratinib, the opportunity for the first time to bring an oral into bladder cancer, we see incredible enthusiasm from urologists in being able to replace this revenue stream that is essentially about to go off patent, and hit their practice revenue.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day